Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of May 21, 2026, KURA trades at $10.27 with a market cap of $816.72M and a P/E ratio of -3.19. KURA moved +15.29% today. Year to date, KURA is +8.39%; over the trailing twelve months it is +62.07%. Its 52-week range spans $5.41 to $19.94. Analyst consensus is strong buy with an average price target of $28.13. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own KURA include Polen Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kura Oncology, Inc..
| Metric | Value |
|---|---|
| Price | $10.27 |
| Market Cap | $816.72M |
| P/E Ratio | -3.19 |
| EPS | $-3.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.94 |
| 52-Week Low | $5.41 |
| Volume | 11.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $67.48M |
| Net Income | $-278.67M |
| Gross Margin | 0.00% |
10 analysts cover KURA: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.13.